Adverse effects of bevacizumab and their management in solid tumors

Yull Arriaga; Carlos R. Becerra

doi:10.3816/SCT.2006.n.023

Adverse effects of bevacizumab and their management in solid tumors

Yull Arriaga, Carlos R. Becerra

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

Original language	English (US)
Pages (from-to)	247-250
Number of pages	4
Journal	Supportive Cancer Therapy
Volume	3
Issue number	4
DOIs	https://doi.org/10.3816/SCT.2006.n.023
State	Published - Jul 2006

Keywords

Bleeding
Gastrointestinal perforations
Hypertension
Proteinuria
Thrombosis
Vascular endothelial growth factor

ASJC Scopus subject areas

Oncology
Pharmacology
Cancer Research

Access to Document

10.3816/SCT.2006.n.023

Cite this

@article{7ab92d05806d4c649bd42062d7ae6e96,

title = "Adverse effects of bevacizumab and their management in solid tumors",

abstract = "Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.",

keywords = "Bleeding, Gastrointestinal perforations, Hypertension, Proteinuria, Thrombosis, Vascular endothelial growth factor",

author = "Yull Arriaga and Becerra, {Carlos R.}",

year = "2006",

month = jul,

doi = "10.3816/SCT.2006.n.023",

language = "English (US)",

volume = "3",

pages = "247--250",

journal = "Supportive Cancer Therapy",

issn = "1543-2912",

publisher = "Cancer Information Group, LP",

number = "4",

}

TY - JOUR

T1 - Adverse effects of bevacizumab and their management in solid tumors

AU - Arriaga, Yull

AU - Becerra, Carlos R.

PY - 2006/7

Y1 - 2006/7

N2 - Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

AB - Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

KW - Bleeding

KW - Gastrointestinal perforations

KW - Hypertension

KW - Proteinuria

KW - Thrombosis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33749464563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749464563&partnerID=8YFLogxK

U2 - 10.3816/SCT.2006.n.023

DO - 10.3816/SCT.2006.n.023

M3 - Article

C2 - 18632501

AN - SCOPUS:33749464563

SN - 1543-2912

VL - 3

SP - 247

EP - 250

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

IS - 4

ER -

Adverse effects of bevacizumab and their management in solid tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this